The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. (October 2018)

• Record Type: Journal Article
• Authors: LaRocca, Nicholas G; Hudson, Lynn D; Rudick, Richard; Amtmann, Dagmar; Balcer, Laura; Benedict, Ralph; Bermel, Robert; Chang, Ih; Chiaravalloti, Nancy D; Chin, Peter; Cohen, Jeffrey A; Cutter, Gary R; Davis, Mat D; DeLuca, John; Feys, Peter; Francis, Gordon; Goldman, Myla D; Hartley, Emily; Kapoor, Raj; Lublin, Fred; Lundstrom, Gary; Matthews, Paul M; Mayo, Nancy; Meibach, Richard; Miller, Deborah M; Motl, Robert W; Mowry, Ellen M; Naismith, Rob; Neville, Jon; Panagoulias, Jennifer; Panzara, Michael; Phillips, Glenn; Robbins, Ann; Sidovar, Matthew F; Smith, Kathryn E; Sperling, Bjorn; Uitdehaag, Bernard MJ; Weaver, Jerry;
• Is Part Of: Multiple sclerosis. Volume 24:Number 11(2018)
• Page Start: 1469
• Page End: 1484
• Publication Date: 2018-10
• Subjects: MS disability -- performance outcome measures -- data standards -- clinical trial database -- regulatory qualification; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458517723718
• Languages: English
• ISSNs: 1352-4585

Abstract

Background: The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed by the National MS Society to develop improved measures of multiple sclerosis (MS)-related disability. Objectives: (1) To assess the current literature and available data on functional performance outcome measures (PerfOs) and (2) to determine suitability of using PerfOs to quantify MS disability in MS clinical trials. Methods: (1) Identify disability dimensions common in MS; (2) conduct a comprehensive literature review of measures for those dimensions; (3) develop an MS Clinical Data Interchange Standards Consortium (CDISC) data standard; (4) create a database of standardized, pooled clinical trial data; (5) analyze the pooled data to assess psychometric properties of candidate measures; and (6) work with regulatory agencies to use the measures as primary or secondary outcomes in MS clinical trials. Conclusion: Considerable data exist supporting measures of the functional domains ambulation, manual dexterity, vision, and cognition. A CDISC standard for MS (http://www.cdisc.org/therapeutic#MS ) was published, allowing pooling of clinical trial data. MSOAC member organizations contributed clinical data from 16 trials, including 14, 370 subjects. Data from placebo-arm subjects are available to qualified researchers. This integrated, standardized dataset is being analyzed to support qualification of disability endpoints by regulatory agencies.